B
Bo Lu
Researcher at Ohio State University
Publications - 390
Citations - 24905
Bo Lu is an academic researcher from Ohio State University. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 58, co-authored 353 publications receiving 21823 citations. Previous affiliations of Bo Lu include Wuhan University of Technology & Wuhan University.
Papers
More filters
Journal ArticleDOI
Silver nanoparticles decorated reduced graphene oxide: Eco-friendly synthesis, characterization, biological activities and embryo toxicity studies.
Chandran Krishnaraj,Vignesh Krishnamoorthi Kaliannagounder,Ramachandran Rajan,Thiyagarajan Ramesh,Cheol Sang Kim,Chan Hee Park,Bo Lu,Soon-Il Yun +7 more
TL;DR: In this paper , the nano hybrid composite of leaves extract, graphene oxide and reduced graphene oxide (rGO) nanocomposite was evaluated for antibacterial and anticancer activities.
Journal ArticleDOI
Microbial antigens-loaded myeloma cells enhance Th2 cell proliferation and myeloma clonogenicity via Th2-myeloma cell interaction.
TL;DR: Taken together, the microbial Ag presenting course of MM-Th2-MM interactions—restricted by MHC class-II—may result in tumor development such that all factors involved in the system could have a potential for myeloma therapeutic intervention.
Journal ArticleDOI
Model assisted sensitivity analyses for hidden bias with binary outcomes.
Giovanni Nattino,Bo Lu +1 more
TL;DR: This work proposes a model assisted sensitivity analysis with binary outcomes for the general 1:k matching design, which provides results equivalent to the conventional nonparametric approach in large sample by introducing a conditional logistic outcome model.
Functions for Optimal Non-Bipartite Matching [R package nbpMatching version 1.5.1]
Cole Beck,Bo Lu,Robert A. Greevy +2 more
Journal ArticleDOI
Targeting Extracellular Signal-Regulated Protein Kinase 1/2 (ERK1/2) in Cancer: An Update on Pharmacological Small-Molecule Inhibitors.
TL;DR: The oncogenic roles, key signaling network, and the single- and dual-target inhibitors of ERK1/2 in preclinical and clinical trials are summarized to shed new light on the discovery of more small-molecule inhibitors ofERK1 /2 as candidate drugs to improve cancer therapeutics.